Lercanidipine HCl 10mg film-coated tablets

1. Name of the medicinal product

Lercanidipine HCl 10mg film-coated tablets Taj Pharma
Lercanidipine HCl 20mg film-coated tablets Taj Pharma

2. Qualitative and quantitative composition

a) Each film-coated tablet contains
lercanidipine hydrochloride                                    10mg
(equivalent to lercanidipine                                    9.4mg

b) Each film-coated tablet contains
lercanidipine hydrochloride                                   20mg
(equivalent to lercanidipine                                  18.8mg

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Film–coated tablet.

Yellow, circular, biconvex tablets, scored on one side.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

4. Clinical particulars

4.1 Therapeutic indications

Lercanidipine HCl is indicated in adults for the treatment of mild to moderate essential hypertension.

4.2 Posology and method of administration

Posology

The recommended dosage is 10mg orally once a day at least 15 minutes before meals; the dose may be increased to 20mg depending on the individual patient’s response.

Dose titration should be gradual, because it may take about 2 weeks before the maximal antihypertensive effect is apparent.

Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of Lercanidipine HCl to therapy with a beta-adrenoceptor blocking drug (atenolol), a diuretic (hydrochlorothiazide) or an angiotensin converting enzyme inhibitor (captopril or enalapril).

Since the dose-response curve is steep with a plateau at doses between 20-30mg, it is unlikely that efficacy will be improved by higher doses; whereas side effects may increase.

Older patients: although the pharmacokinetic data and clinical experience suggest that no adjustment of the daily dosage is required, special care should be exercised when initiating treatment in the elderly.

Patients with renal or hepatic impairment: special care should be exercised when treatment is commenced in patients with mild to moderate renal or hepatic dysfunction. Although the usually recommended dose schedule may be tolerated by these subgroups, an increase in dose to 20mg daily must be approached with caution. The antihypertensive effect may be enhanced in patients with hepatic impairment and consequently an adjustment of the dosage should be considered.

Lercanidipine HCl is contraindicated in patients with severe hepatic impairment or in patients with severe renal impairment (GFR < 30 ml/min), including patients undergoing dialysis (see sections 4.3 and 4.4)

Paediatric population : the safety and efficacy of Lercanidipine HCl in children aged up to 18 years have not been established.

No data are available.

Method of administration

For oral use.

Precautions to be taken before handling or administering the medicinal product:

– Treatment should be preferably administered in the morning at least 15 minutes before breakfast.

– This product should not been administered with grapefruit juice (see section 4.3 and 4.5).

4.3 Contraindications

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Left ventricular outflow tract obstruction.
• Untreated congestive cardiac failure.
• Unstable angina pectoris or recent (within 1 month) myocardial infarction.
• Severe hepatic impairment.
• Severe renal impairment (GFR < 30 ml/min), including patients undergoing dialysis.
• Co-administration with:

o strong inhibitors of CYP3A4 (see section 4.5),

o cyclosporin (see section 4.5),

o grapefruit or grapefruit juice (see section 4.5).

4.4 Special warnings and precautions for use

Sick sinus syndrome

Lercanidipine should be administered with caution in patients with sick sinus syndrome (without a pacemaker).

Left ventricular dysfunction

Although hemodynamic controlled studies revealed no impairment of ventricular function, care is also required in patients with left ventricular dysfunction.

Ischaemic heart disease

It has been suggested that some short-acting dihydropyridines may be associated with increased cardiovascular risk in patients with ischaemic heart disease. Although lercanidipine is long-acting, caution is required in such patients. Some dihydropyridines may rarely lead to precordial pain or angina pectoris. Very rarely patients with pre-existing angina pectoris may experience increased frequency, duration or severity of these attacks. Isolated cases of myocardial infarction may be observed (see section 4.8).

Use in renal or hepatic impairment

Special care should be exercised when treatment is commenced in patients with mild to moderate renal impairment Although the usual recommended dose of 10mg daily may be tolerated, an increase to 20mg daily should be approached with caution.

The antihypertensive effect may be enhanced in patients with moderate hepatic impairment and consequently an adjustment of the dosage should be considered.

Lercanidipine is contraindicated in patients with severe hepatic impairment or renal impairment (GFR < 30 ml/min), including patients undergoing haemodialysis (see section 4.2 and section 4.3).

Peritoneal Dialysis

Lercanidipine has been associated with the development of cloudy peritoneal effluent in patients on peritoneal dialysis. The turbidity is due to an increased triglyceride concentration in the peritoneal effluent. Whilst the mechanism is unknown, the turbidity tends to resolve soon after withdrawal of lercanidipine. This is an important association to recognise as cloudy peritoneal effluent can be mistaken for infective peritonitis with consequential unnecessary hospitalisation and empiric antibiotic administration.

Inducers of CYP3A4

Inducers of CYP3A4 like anticonvulsants (e.g. phenytoin, carbamazepine) and rifampicin may reduce lercanidipine plasma levels and therefore the efficacy of lercanidipine may be less than expected (see section 4.5).

Alcohol

Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs (see section 4.5).

Lactose

This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Paediatric population

The safety and efficacy of lercanidipine have not been demonstrated in children.

4.5 Interaction with other medicinal products and other forms of interaction

Contraindications of concomitant use

Inhibitors of CYP3A4

Lercanidipine is known to be metabolised by the CYP3A4 enzyme and therefore inhibitors of CYP3A4 administered concurrently may interact with the metabolism and elimination of lercanidipine. An interaction study with a strong CYP3A4 inhibitor, ketoconazole, has shown a considerable increase in plasma levels of lercanidipine (a 15-fold increase of the AUC and an 8-fold increase of the C_max for the eutomer S-lercanidipine).

Co-prescription of lercanidipine with inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, ritonavir, erythromycin, troleandomycin, clarithromycin) should be avoided (see section 4.3).

Cyclosporin

Increased plasma levels of both lercanidipine and cyclosporin have been observed following concomitant administration. A study in young healthy volunteers has shown that when cyclosporin was administered 3 hours after the lercanidipine intake, the plasma levels of lercanidipine did not change, while the AUC of cyclosporin increased by 27%. However, the co-administration of lercanidipine with cyclosporin has caused a 3-fold increase of the plasma levels of lercanidipine and a 21% increase of the cyclosporin AUC.

Cyclosporin and lercanidipine should not be administered together (see section 4.3).

Grapefruit or grapefruit juice

As for other dihydropyridines, lercanidipine is sensitive to inhibition of metabolism by grapefruit or grapefruit juice, with a consequent rise in its systemic availability and increased hypotensive effect.

Lercanidipine should not be taken with grapefruit or grapefruit juice (see section 4.3).

Concomitant use not recommended

Inducers of CYP3A4

Co-administration of lercanidipine with CYP3A4 inducers like anticonvulsants (e.g. phenytoin, phenobarbital, carbamazepine) and rifampicin should be approached with caution since the antihypertensive effect may be reduced and blood pressure should be monitored more frequently than usual (see section 4.4).

Alcohol

Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs (see section 4.4).

Precautions including dose adjustment

Substrates of CYP3A4

Caution should be exercised when lercanidipine is co-prescribed with other substrates of CYP3A4, like terfenadine, astemizole, class III antiarrhythmic drugs such as amiodarone, quinidine, sotalol.

Midazolam

When concomitantly administered at a dose of 20mg with midazolam p.o. to elderly volunteers, lercanidipine absorption was increased (by approximately 40%) and the rate of absorption was decreased (t_max was delayed from 1.75 to 3 hours). Midazolam concentrations were not modified.

Metoprolol

When lercanidipine was co-administered with metoprolol, a ß-blocker eliminated mainly by the liver, the bioavailability of metoprolol was not changed while that of lercanidipine was reduced by 50%. This effect may be due to the reduction in the hepatic blood flow caused by ß-blockers and may therefore occur with other drugs of this class. Consequently, lercanidipine may be safely administered with β-adrenoceptor blocking drugs, but dose adjustment may be required.

Digoxin

Co-administration of 20mg lercanidipine in patients chronically treated with β-methyldigoxin showed no evidence of pharmacokinetic interaction. However, a mean increase of 33% in digoxin C_max was observed, while AUC and renal clearance were not significantly modified. Patients on concomitant digoxin treatment should be closely monitored clinically for signs of digoxin toxicity.

Concomitant use with other drugs

Fluoxetine

An interaction study with fluoxetine (an inhibitor of CYP2D6 and CYP3A4), conducted in volunteers of an age of 65 ± 7 years (mean ± s.d.), has shown no clinically relevant modification of the pharmacokinetics of lercanidipine.

Cimetidine

Concomitant administration of cimetidine 800mg daily does not cause significant modifications in plasma levels of lercanidipine, but at higher doses caution is required since the bioavailability and the hypotensive effect of lercanidipine may be increased.

Simvastatin

When a dose of 20mg of lercanidipine was repeatedly co-administered with 40mg of simvastatin, the AUC of lercanidipine was not significantly modified, while simvastatin AUC increased by 56% and that of its active metabolite ß-hydroxyacid by 28%. It is unlikely that such changes are of clinical relevance. No interaction is expected when lercanidipine is administered in the morning and simvastatin in the evening, as indicated for such drug.

Diuretics and ACE inhibitors

Lercanidipine has been safely administered with diuretics and ACE inhibitors.

Other medications affecting blood pressure

As for all antihypertensive medications, an increased hypotensive effects may be observed when lercanidipine is administered with other medications affecting blood pressure, such as alphablockers for the treatment of urinary symptoms, tricyclic antidepressants, neuroleptics. On the contrary, a reduction of the hypotensive effect may be observed with a concomitant use with corticosteroids.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no data from the use of lercanidipine in pregnant women. Studies in animals have not shown teratogenic effects (see section 5.3), but these have been observed with other dihydropyridine compounds. Lercanidipine is not recommended during pregnancy and in women of childbearing-potential not using contraception.

Breast-feeding

It is unknown whether lercanidipine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Lercanidipine should not be used during breastfeeding.

Fertility

No clinical data are available with lercanidipine. Reversible biochemical changes in the head of spermatozoa which can impair fecundation have been reported in some patients treated by channel blockers. In cases where repeated in-vitro fertilisation is unsuccessful and where another explanation cannot be found, the possibility of calcium channel blockers as the cause should be considered

4.7 Effects on ability to drive and use machines

Lercanidipine has minor influence on the ability to drive and use machines. However, caution should be exercised because dizziness, asthenia, fatigue and rarely somnolence may occur.

4.8 Undesirable effects

Summary of safety profile

The safety of lercanidipine at a dose of 10-20mg once daily has been evaluated in double-blind, placebo-controlled clinical trials (with 1200 patients receiving lercanidipine and 603 patients receiving placebo) and in active-controlled and uncontrolled long term clinical trials on a total of 3676 hypertensive patients receiving lercanidipine.

The most commonly reported adverse reactions in clinical trials and in the post-marketing experience are: peripheral oedema, headache, flushing, tachycardia and palpitations.

Tabulated list of adverse reactions

In the table below, adverse reactions reported in clinical trials and in the worldwide post-marketing experience for which a reasonable causal relationship exists are listed by MedDRA system organ class and frequency: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from available data). Within each frequency grouping the observed adverse reactions are presented in order of decreasing seriousness.

¹adverse reactions from spontaneous reporting in the worldwide post-marketing experience

Description of selected adverse reactions

In placebo controlled clinical trials the incidence of peripheral oedema was 0.9% with lercanidipine 10-20mg and 0.83% with placebo. This frequency reached 2% in the overall study population including long term clinical trials.

Lercanidipine does not appear to influence adversely blood sugar or serum lipid levels.

Some dihydropyridines may rarely lead to precordial pain or angina pectoris. Very rarely patients with pre-existing angina pectoris may experience increased frequency, duration or severity of these attacks. Isolated cases of myocardial infarction may be observed.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

4.9 Overdose

In the post-marketing experience of lercanidipine, some cases of overdose have been reported ranging from 30-40mg up to 800mg, including reports of suicide attempt.

Symptoms

As with other dihydropyridines, lercanidipine overdosage results in excessive peripheral vasodilatation with marked hypotension and reflex tachycardia. However, at very high doses, the peripheral selectivity may be lost, causing bradycardia and a negative inotropic effect. The most common ADRs associated to cases of overdose have been hypotension, dizziness, headache and palpitations.

Treatment

Clinically significant hypotension requires active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output. In view of the prolonged pharmacological effect of lercanidipine, it is essential that the cardiovascular status of the patient is monitored for 24 hours at least. Since the product has a high protein binding, dialysis is not likely to be effective. Patients in whom a moderate to severe intoxication is anticipated should be observed in a high-care setting.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Selective calcium channel blockers with mainly vascular effects – Dihydropyridine derivatives

Mechanism of action

Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance.

Pharmacodynamic effects

Despite its short pharmacokinetic plasma half-life, lercanidipine is endowed with a prolonged antihypertensive activity because of its high membrane partition coefficient, and is devoid of negative inotropic effects due to its high vascular selectivity.

Since the vasodilatation induced by Lercanidipine HCl is gradual in onset, acute hypotension with reflex tachycardia has rarely been observed in hypertensive patients.

As for other asymmetric 1,4-dihydropyridines, the antihypertensive activity of lercanidipine is mainly due to its (S)-enantiomer.

Clinical efficacy and safety

The clinical efficacy and safety of lercanidipine at a dose of 10-20mg once daily has been evaluated in double-blind, placebo-controlled clinical trials (with 1200 patients receiving lercanidipine and 603 patients receiving placebo) and in active-controlled and uncontrolled long term clinical trials on a total of 3676 hypertensive patients.

Most clinical trials have been conducted in patients with mild to moderate essential hypertension (including elderly and diabetic patients), receiving lercanidipine alone or in combination with ACE-Is, diuretics or beta-blockers.

In addition to the clinical studies conducted to support the therapeutic indications, a further small uncontrolled but randomised study of patients with severe hypertension (mean + SD diastolic blood pressure of 114.5 + 3.7 mmHg) showed that blood pressure was normalised in 40% of the 25 patients on 20mg once daily dose and in 56% of 25 patients on 10mg twice daily doses of Lercenidipine HCl. In a double-blind, randomized, controlled study versus placebo in patients with isolated systolic hypertension Lercanidipine HCl was efficacious in lowering systolic blood pressure from mean initial values of 172.6 + 5.6 mmHg to 140.2 + 8.7 mmHg.

No clinical trial has been performed in the paediatric population.

5.2 Pharmacokinetic properties

Absorption

Lercanidipine HCl is completely absorbed after 10-20mg oral administration and peak plasma levels, 3.30 ng/ml + 2.09 s.d. and 7.66 ng/ml + 5.90 s.d. respectively, occur about 1.5-3 hours after dosing.

The two enantiomers of lercanidipine show a similar plasma level profile: the time to peak plasma concentration is the same, the peak plasma concentration and AUC are, on average, 1.2-fold higher for the (S) enantiomer and the elimination half-lives of the two enantiomers are essentially the same. No “in vivo” interconversion of enantiomers is observed.

Due to the high first pass metabolism, the absolute bioavailability of Lercanidipine HCl orally administered to patients under fed conditions is around 10%, although it is reduced to 1/3 when administered to healthy volunteers under fasting conditions.

Oral availability of lercanidipine increases 4-fold when Lercanidipine HCl is ingested up to 2 hours after a high fat meal. Accordingly, Lercanidipine HCl should be taken before meals.

Distribution

Distribution from plasma to tissues and organs is rapid and extensive.

The degree of serum protein binding of lercanidipine exceeds 98%. Since plasma protein levels are reduced in patients with severe renal or hepatic dysfunction, the free fraction of the drug may be increased.

Biotransformation

Lercanidipine HCl is extensively metabolised by CYP3A4; no parent drug is found in the urine or the faeces. It is predominantly converted to inactive metabolites and about 50% of the dose is excreted in the urine.

“In vitro” experiments with human liver microsomes have demonstrated that lercanidipine shows some degree of inhibition of CYP3A4 and CYP2D6, at concentrations 160- and 40-fold, respectively, higher than those reached at peak in the plasma after the dose of 20mg.

Moreover, interaction studies in humans have shown that lercanidipine did not modify the plasma levels of midazolam, a typical substrate of CYP3A4, or of metoprolol, a typical substrate of CYP2D6. Therefore, inhibition of biotransformation of drugs metabolised by CYP3A4 and CYP2D6 by Lercanidipine HCl is not expected at therapeutic doses.

Elimination

Elimination occurs essentially by biotransformation.

A mean terminal elimination half-life of 8-10 hours was calculated and the therapeutical activity lasts for 24 hours because of its high binding to lipid membrane. No accumulation was seen upon repeated administration.

Linearity/non-linearity

Oral administration of Lercanidipine HCl leads to plasma levels of lercanidipine not directly proportional to dosage (non-linear kinetics). After 10, 20 or 40mg, peak plasma concentrations observed were in the ratio 1:3:8 and areas under plasma concentration-time curves in the ratio 1:4:18, suggesting a progressive saturation of first pass metabolism. Accordingly, availability increases with dosage elevation.

Additional information on special populations

In elderly patients and in patients with mild to moderate renal dysfunction or mild to moderate hepatic impairment the pharmacokinetic behaviour of lercanidipine was shown to be similar to that observed in the general patient population; patients with severe renal dysfunction or dialysis-dependent patients showed higher levels (about 70%) of the drug. In patients with moderate to severe hepatic impairment, the systemic bioavailability of lercanidipine is likely to be increased since the drug is normally metabolised extensively in the liver.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for human based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

Safety pharmacological studies in animals have shown no effects on the autonomic nervous system, the central nervous system or on gastrointestinal function at antihypertensive doses.

The relevant effects which have been observed in long-term studies in rats and dogs were related, directly or indirectly, to the known effects of high doses of Ca-antagonists, predominantly reflecting exaggerated pharmacodynamic activity.

Lercanidipine was not genotoxic and showed no evidence of carcinogenic hazard.

Fertility and general reproductive performance in rats were unaffected by treatment with lercanidipine.

There was no evidence of any teratogenic effect in rats and rabbits; however, in rats, lercanidipine at high dose levels induced pre- and post- implantation losses and delay in foetal development.

Lercanidipine hydrochloride, when administered at high dose (12mg/kg/day) during labour, induced dystocia.

The distribution of lercanidipine and/or its metabolites in pregnant animals and their excretion in breast milk have not been investigated.

Metabolites have not been evaluated separately in toxicity studies.

6. Pharmaceutical particulars

6.1 List of excipients

Tablet core:

Lactose monohydrate, Microcrystalline cellulose, Sodium starch glycolate

Povidone, Magnesium stearate

Film coating:

Hypromellose, Talc, Titanium dioxide, Macrogol, Ferric oxide

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Store in the original package in order to protect from light.

6.5 Nature and contents of container

Aluminium/opaque PVC blisters.

Packs of 7, 14, 28, 35, 42, 50, 56, 98 and 100 tablets.*

* Not all pack sizes may be marketed.

7. Manufactured By:
   Taj Pharmaceuticals Ltd.
   at: Plot. No. 220, Mahagujarat
   Industrial Estate, At & Post-Moraiya,
   Tal-Sanand, Dist- Ahmedabad Gujarat (India)

Lercanidipine HCl 10mg/20mg Tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER

Lercanidipine HCl 10mg film-coated tablets Taj Pharma
Lercanidipine HCl 20mg film-coated tablets Taj Pharma

lercanidipine hydrochloride

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it
• If you have any further questions, ask your doctor or
• This medicine has been prescribed for you Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section

What is in this leaflet:

1. What Lercanidipine HCl is and what it is used for
2. What you need to know before you take Lercanidipine HCl
3. How to take Lercanidipine HCl
4. Possible side effects
5. How to store Lercanidipine HCl
6. Contents of the pack and other information

1.             What Lercanidipine HCl is and what it is used for

Lercanidipine HCl, lercanidipine hydrochloride, belongs to a group of medicines called Calcium Channel Blockers (dihydropyridine derivatives)that lower blood pressure.

Lercanidipine HCl is used to treat high blood pressure also known as hypertension in adults over the age of 18 years (it is not recommended for children under 18 years old).

What you need to know before you take Lercanidipine HCl Do not take Lercanidipine HCl:

• If you are allergic (hypersensitive) to lercanidipine hydrochloride or to any other ingredients of Lercanidipine HCl
• If you are suffering from certain heart diseases:

• obstruction to flow of blood from the heart
• untreated heart failure
• unstable angina (chest discomfort occurring at rest or progressively increasing)
• within one month of heart
  • If you have severe liver
  • If you have severe kidney problems or you are undergoing

If you are taking medicines that are inhibitors of the hepatic metabolism, such as: o antifungal medicines (such as ketoconazole or itraconazole)

• macrolide antibiotics (such as erythromycin, troleandomycin or clarithromycin)
• antivirals (such as ritonavir)
  • If you are taking another medicine called ciclosporin or cyclosporin (used after transplants to prevent organ rejection).
  • With grapefruit or grapefruit

Warnings and precautions

Talk to your doctor or pharmacist before taking Lercanidipine HCl:

• if you have a heart problem
• if you have liver or kidneys problems

You must tell your doctor if you think you are (or might become) pregnant or breast-feeding (see pregnancy, breast-feeding and fertility section).

Children and adolescents

The safety and efficacy of Lercanidipine HCl in children aged up to 18 years have not been established.

Other medicines and Lercanidipine HCl

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because when Lercanidipine HCl is taken with other medicines the effect of Lercanidipine HCl or of the other medicine may be changed or certain side effects may occur more frequently (see also section 2 “Do not take Lercanidipine HCl”).

In particular, tell your doctor or pharmacist if you are taking any of the following medicines:

• phenytoin, phenobarbital or carbamazepine (medicines for epilepsy)
• rifampicin (a medicine to treat tubercolosis)
• astemizole or terfenadine (medicines for allergies)
• amiodarone, quinidine or sotalol (medicines to treat a fast heart beat)
• midazolam (a medicine that helps you sleep)
• digoxin (a medicine to treat a heart problem)
• beta-blockers e.g. metoprolol (a medicine to treat high blood pressure, heart failure and abnormal heart rhythms)
• cimetidine (more than 800mg, a medicine for ulcers, indigestion, or heartburn)
• simvastatin (a medicine to lower cholesterol in your blood)
• other medicines to treat high blood pressure

Lercanidipine HCl with food, drink and alcohol

• A high fat meal significantly increases blood levels of the medicine (see section 3).
• Alcohol can increase the effect of Lercanidipine HCl. Do not consume alcohol during treatment with Lercanidipine HCl
• Lercanidipine HCl must not be taken with grapefruit or grapefruit juice (they can increase its hypotensive effect). See section 2 – Do not take Lercanidipine

Pregnancy, breast-feeding and fertility

Lercanidipine HCl is not recommended if you are pregnant, it should not be used during breast- feeding. There are no data from the use of Lercanidipine HCl in pregnant women and in nursing mothers. If you are pregnant or breast-feeding, if you are not using any contraceptive method, you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine

Driving and using machines

If you develop dizziness, weakness or drowsiness with this medicine, do not drive a vehicle or operate machines.

Lercanidipine HCl contains lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

2. How to take Lercanidipine HCl

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Adults: the recommended dose is 10mg once daily, at the same time each day, preferably in the morning at least 15 minutes before breakfast. Your doctor may advise you to increase the dose to one Lercanidipine HCl 20mg daily, if needed (see section 2 “Lercanidipine HCl with food, drink and alcohol”).

The tablets should preferably be swallowed whole with some water.

Use in children: this medicine should not be used in children under 18 years of age.

Elderly patients: no adjustment of the daily dose is required. However, special care should be exercised in starting treatment.

Patients with liver or kidney problems: special care is needed in starting treatment in these patients and an increase in daily dose to 20mg should be approached with caution.

If you have any further questions on the use of this medicine ask your doctor or pharmacist.

If you take more Lercanidipine HCl than you should

Do not exceed the prescribed dose. If you have taken more than the prescribed dose, talk to your doctor or go to the hospital straight away. Take the medicine pack with you. Taking more than the correct dose can cause an excessive drop in blood pressure and your heart can beat irregularly or faster.

If you forget to take Lercanidipine HCl

If you forget to take your tablet simply miss that dose and then go on as before. Do not take a double dose to make up for a forgotten dose.

If you stop taking Lercanidipine HCl

If you stop taking Lercanidipine HCl your blood pressure may increase again. Please consult your doctor before stopping the treatment.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

3.   Possible side effects 

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:

Some side effects can be serious.

If any of the following happen, tell your doctor straight away:

Rare (may affect up to 1 in 1,000 people): angina pectoris (e.g. chest tightness due to lack of blood to your heart), allergic reactions (symptoms include itching, rash, urticaria), fainting.

Patients with pre-existing angina pectoris may experience increased frequency, duration or severity of these attacks with the group of medicines to which Lercanidipine HCl belongs. Isolated cases of heart attack may be observed.

Other possible side effects:

Common (may affect up to 1 in 10 people): headache, faster heart rate, feeling of fast or uneven heart beat (palpitations), sudden reddening of your face, neck or upper chest (flushing), ankle swelling.

Uncommon (may affect up to 1 in 100 people): dizziness, fall in blood pressure, heartburn, feeling sick, stomach pain, skin rash, itching, muscle pain, passage of large amounts of urine, feeling weak or feeling tired.

Rare (may affect up to 1 in 1,000 people): sleepiness, vomiting, diarrhoea, hives, increase in the usual number of times one urinates, chest pain.

Not known (frequency cannot be estimated from the available data): swelling of gums, changes in liver function (detected by blood tests), cloudy fluid (when performing dialysis through a tube into your abdomen), swelling of your face, lip, tongue or throat which may cause difficulty in breathing or swallowing.

Reporting of suspected adverse reactions

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

4.   How to store Lercanidipine HCl

Keep this medicine out of the sight and reach of children

Do not use this medicine after the expiry date, which is stated on the carton and on blister after EXP. The expiry date refers to the last day of that month.

Store in the original package in order to protect from light

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information What Lercanidipine HCl contains

The active substance is lercanidipine hydrochloride.

Each film-coated tablet contains 10mg lercanidipine hydrochloride (equivalent to 9.4mg lercanidipine) or 20mg lercanidipine hydrochloride(equivalent to 18.8mg lercanidipine).

The other ingredients are:

Tablet core: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, povidone K30, magnesium stearate.

Film coating: hypromellose, talc, titanium dioxide, macrogol, ferric oxide.

What Lercanidipine HCl looks like and contents of the pack

Lercanidipine HCl film coated tablet  film coated tablet scored on one side.

Lercanidipine HCl is available in blister packs of 7, 14, 28, 35, 42, 50, 56, 98, 100 tablets. Not all pack sizes may be marketed.

7.  Manufactured By:
Taj Pharmaceuticals Ltd.
at: Plot. No. 220, Mahagujarat
Industrial Estate, At & Post-Moraiya,
Tal-Sanand, Dist- Ahmedabad Gujarat (India)